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Abstract
Toremifene citrate is expected to prevent drug resistance in cancer patients by inhibiting p-
glycoprotein activity. The safety and efficacy of combination therapy with high-dose toremifene
citrate and paclitaxel were investigated. Between December 2003 and June 2004, 15 women with a
mean age of 53 years old with metastatic breast cancer were enrolled. The administration schedule
was 80mg/m2 of paclitaxel given on Days 1, 8, and 15, and 120mg/day of toremifene citrate orally
administered starting on Day 18. On Days 32 and 39, paclitaxel was concurrently administered
again. Toxicities, response rate, and time to treatment failure were assessed. All patients had
been treated with endocrine or chemotherapy. Grade 3 leukopenia occurred in 2 patients on the
administration of paclitaxel alone, and grade 3 febrile neutropenia occurred in 1 patient given the
combination therapy. There was no grade 3 or greater non-hematological toxicity. There was
no complete response and 1 partial response, producing a response rate of 6.7%. Median time
to treatment failure was 2.7 months. Combination therapy of paclitaxel and toremifene was safe
and well tolerated with minimal toxicity. Further clinical trials targeting patients with functional
p-glycoprotein are warranted.
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Toremifene citrate is expected to prevent drug resistance in cancer patients by inhibiting p-glycopro-
tein activity.  The safety and eﬃcacy of combination therapy with high-dose toremifene citrate and 
paclitaxel were investigated.  Between December 2003 and June 2004,  15 women with a mean age of 53 
years old with metastatic breast cancer were enrolled.  The administration schedule was 80mg/m2 of 
paclitaxel given on Days 1,  8,  and 15,  and 120mg/day of toremifene citrate orally administered start-
ing on Day 18.  On Days 32 and 39,  paclitaxel was concurrently administered again.  Toxicities,  
response rate,  and time to treatment failure were assessed.  All patients had been treated with endo-
crine or chemotherapy.  Grade 3 leukopenia occurred in 2 patients on the administration of paclitaxel 
alone,  and grade 3 febrile neutropenia occurred in 1 patient given the combination therapy.  There was 
no grade 3 or greater non-hematological toxicity.  There was no complete response and 1 partial 
response,  producing a response rate of 6.7ｵ.  Median time to treatment failure was 2.7 months.  
Combination therapy of paclitaxel and toremifene was safe and well tolerated with minimal toxicity.  
Further clinical trials targeting patients with functional p-glycoprotein are warranted.
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etastatic breast cancer is considered incurable 
and optimal palliation and prolongation of life 
rather than curative intent are the main goals of treat-
ment [1,  2].  Anthracycline-containing regimens have 
been the most eﬀective against this disease [3] and 
until recently,  there was no standard treatment for 
patients with metastatic breast cancer in whom an 
anthracycline-containing regimen was ineﬀective.  
However,  taxanes have proved to be equally as eﬃca-
cious as anthracycline [4],  and anthracycline and 
taxanes are now considered the most active chemo-
therapeutic agents for metastatic breast cancer [5].  
Taxanes have also demonstrated signiﬁcant activity as 
second- and third-line agents in the treatment of meta-
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static breast cancer [4,  6].  However,  tumors initially 
sensitive to agents often acquire a multidrug resis-
tance (MDR) phenotype,  which is characterized by 
cross resistance to drugs to which the tumor has not 
been exposed [7].  A number of mechanisms have been 
identiﬁed for the resistance to chemotherapeutic 
agents.  As one form of resistance,  p-glycoprotein 
encoded by MDR1 as an energy-dependent drug eﬄux 
pump can acquire resistance to structurally unrelated 
compounds simultaneously [8].  Toremifene citrate 
was developed in the 1980s,  as a safe,  less toxic,  and 
non-steroidal triphenylethylene antiestrogen and 
became widely used in the treatment of postmeno-
pausal breast cancer [9-11].  Toremifene citrate was 
an aﬃnity substrate for the p-glycoprotein capable of 
interfering with the transport catalyzed by the p-gly-
coprotein [12].  Toremifene citrate in combination 
with paclitaxel is expected to be eﬀective against 
breast cancer,  however,  both agents are mainly 
degraded via the same pathway by the hepatic enzyme 
cytochrome P450 [13,  14] and thier combination in 
treatment might induce an increase in plasma concen-
trations or severe side eﬀects.  We designed this 
prospective study to assess whether high-dose tore-
mifene citrate in addition to paclitaxel would be safe 
for or beneﬁcial to patients with metastatic breast 
cancer.
Patients and Methods
　 Patients and Eligibility criteria. Patients 
with metastatic breast cancer were considered for 
enrollment.  Eligibility criteria were as follows: 1) age 
of 80 years or younger; 2) Eastern Cooperative 
Oncology Group (ECOG) performance status of 2 or 
less; 3) recovery from the toxic eﬀects of previous 
therapy; 4) adequate bone marrow,  liver and renal 
function; 5) without severe cardiac disease; and 6) 
more than 3 months predictive survival.  Eligibility 
was independent of estrogen receptor status.  Previous 
treatments including taxanes were not considered in 
the eligibility criteria.  This study was performed at 
the Shikoku Cancer Center.  The protocol was 
approved by the institutional review board of Shikoku 
Cancer Center and was carried out in accordance with 
the Helsinki Declaration.  All patients gave their writ-
ten informed consent before entry and the partici-
pantsʼ identiﬁcation codes were used for unequivocal 
identiﬁcation of the patients.  Patients were excluded 
if they had a high risk of a poor outcome because of 
concomitant nonmalignant disease,  an active double 
cancer,  and any other reason for which the investiga-
tor judged the patient to be unsuited for inclusion or 
unable to cooperate in the study.
　 Study design. Paclitaxel was administered 
intravenously on day 1,  8,  15,  32 and 39 and oral 
toremifene was administered daily from day 18.  Pac-
litaxel was administered by intravenous infusion for 
1.5h at a dose of 80mg/m2 and toremifene was admin-
istered at 120mg/body once every day (Fig.  1).  This 
study was stopped on day 39,  after which,  paclitaxel 
was administered weekly for 3 consecutive weeks,  
followed by an one-week rest period and toremifene 
was concurrently administered orally every day.  Pro-
phylactic colony-stimulating factor (G-CSF) was used 
to determine whether neutropenic complications had 
occurred in a previous cycle.
　 Given the lack of appropriate pharmacological data,  
many questions remain about the use of toremifene for 
reversal of MDR including optimal dose and optimal 
schedule.  In an in vitro experiment,  a toremifene con-
centration of more than 2µM reversed resistance,  but 
this phenomenon was shown to be highly inﬂuenced by 
serum proteins in vivo [15].  In patients receiving 
toremifene to reverse doxorubicin resistance,  it must 
be assumed that toremifene was extensively protein 
bound (＞95ｵ) and that toremifene concentrations in 
the order of ＞10µM were required to overcome the 
eﬀects of protein binding in plasma [15].  On the basis 
of pharmacological studies [16,  17],  a dose of 120mg 
per day was enough to maintain the plasma concentra-
tion necessary to reverse drug resistance.  In addition,  
the time required to achieve a steady-state plasma 
concentration of toremifene and its metabolites was 
more than 2 weeks [18].  The present regimen was 
designed with these data in mind.
　 Safety evaluation. On the day before the 




1 8 15 18 32 39
Regimen
Fig. 1　 Treatment schedule of weekly paclitaxel and toremifene.
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administration of paclitaxel,  laboratory tests were 
performed as follows; complete blood cell counts,  
diﬀerential white blood cell count,  serum glutamic 
oxaloacetic transaminase,  serum glutamic pyruvic 
transaminase,  lactate dehydrogenase,  gamma-glutamyl 
transpeptidase,  cholinesterase,  total cholesterol,  
electrolytes,  total bilirubin,  direct bilirubin,  alkaline 
phosphatase,  leucine aminopeptidase,  total protein,  
albumin,  albumin/globulin ratio,  blood urea nitrogen,  
triglyceride,  zinc sulfate turbidity test,  thymol tur-
bidity test,  carcinoembryonic antigen,  carbohydrate 
antigen 15-3,  urinalysis and creatinine clearance.  
Doctors also interviewed patients to take a history of 
adverse events and physical examination.  Toxicities 
were evaluated according to National Cancer 
Institute-Common Toxicity Criteria (NCI-CTC) ver-
sion 2.0.  The primary end point was the incidence of 
adverse events.
　 Evaluation of response. The objective 
response to chemotherapy was evaluated by the 
General Rules for Clinical and Pathological Recording 
of Breast Cancer (The Japanese Breast Cancer 
Society.  14th edition).  Response assessment was 
performed every 1 or 2 months by serial clinical,  
radiographic,  or computed tomographic measurement.  
A complete response (CR) was deﬁned as the disap-
pearance of all evidence of cancer for at least 4 weeks,  
and a partial response (PR) was deﬁned as less than a 
complete response,  but more than a 50ｵ reduction of 
tumor volume for at least 4 weeks,  without any evi-
dence of new lesions or progression.  No change (NC) 
was deﬁned as less than a 50ｵ reduction or less than 
a 25ｵ increase with no new lesions.  Progressive 
disease (PD) was deﬁned as more than a 25ｵ 
increase in a solitary lesion or the appearance of new 
lesions.  Stable disease (SD) was deﬁned as neither 
suﬃcient shrinkage to qualify for PR nor a suﬃcient 
increase to qualify for PD for more than 6 months.  
We also deﬁned the disease control rate as the sum of 
CR,  PR and SD to evaluate the potential beneﬁts of 
this treatment.
　 Time to treatment failure. Time to treatment 
failure was calculated by the Kaplan-Meier method 
from the day of the initiation of the concurrent admin-
istration of toremifene and paclitaxel until the date of 
progression,  death (any cause) or withdrawal owning 
to an adverse event,  or patient refusal.  StatView 5.0 
software (SAS Institute,  Inc.,  Cary,  NC,  USA) was 
used throughout this study.
Results
　 This study was carried out between December,  
2003,  and June,  2004,  and enrolled a total of ﬁfteen 
women who had metastatic breast cancer.  Charac-
teristics of patients are listed in Table 1.  There were 
15 women with an average age of 53.0 years.  Thirteen 
patients had a performance status of 2 or less.  Two 
patients had a performance status of 3,  because of 
metastasis to vertebrae which obliged them to be 
bedridden however,  they were considered capable of 
tolerating the treatment.  Frequent metastatic tumor 
189Paclitaxel and ToremifeneAugust 2009
Table 1　 Patient characteristics
Total patients 15 women
Age (range) 53.0±12.8 (33－77) yrs.




Menopausal state Premenopausal 6
Postmenopausal 9
Prior treatment Anthracycline 14
Taxane 11 (Paclitaxel: 9, Docetaxel: 9)
5-FU 10
Endocrine 14
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sites included the bone in 11 patients,  the liver in 10 
patients and the lung in 8 patients and metastases to 3 
or more sites were observed in 7 patients.  A total of 
11 patients (73ｵ) had received prior taxane therapy.  
Two patients had received paclitaxel,  2 patients (1 in 
a neoadjuvant setting) had received docetaxel,  and 7 
patients (1 who received docetaxel in a neoadjuvant 
setting) had received both.  There was no patient who 
had received taxane therapy in an adjuvant setting.  
Characteristics of primary lesions are shown in Table 
2.  Twelve patients had recurrent disease; 10 of these 
after a curative operation and 2 patients after neoad-
juvant chemotherapy and a curative operation.  Three 
patients had metastatic disease on ﬁrst arrival; 2 had 
received chemotherapy and surgery because their 
quality of life was impaired,  and 1 patient received 
only chemotherapy.  Eleven patients tested positive for 
estrogen receptors.  No patients showed strong HER2 
expression.
　 A total of 112 accomplished combination treatment 
cycles (median 7.5,  range 1-25) were administered.
　 Non-hematological toxicities are listed in Table 
3A.  There were no patients with grade 3 or greater 
toxicity.  Frequent toxic symptoms included nausea,  
vomiting,  alopecia,  myalgia,  arthralgia,  and ﬂushing.  
During the combination therapy,  vaginal discharge 
was found in 3 patients.  Hematological toxicities are 
noted in Table 3B.  Only 1 patient (6.7ｵ) had grade 3 
febrile neutropenia.  According to the lipid eﬀects,  
hypercholesterolemia was improved but hyperglyceri-
demia worsened.  Overall the therapy was generally 
well tolerated and there were no toxicity-associated 
deaths.
　 Table 4 summaries the results of chemotherapy.  
Of all patients,  1 partially responded and the response 
rate was 6.7ｵ.  Ten patients (66.7ｵ) showed no 
change and 4 of them (26.7ｵ) were stabilized for 6 
months or more.  The disease control rate summarizes 
complete responses,  partial responses and stable dis-
ease,  thereby accounting for the overall beneﬁt from 
treatment,  and was 33.3ｵ (5 of 15 patients).  Four 
patients (26.7ｵ) had progressive disease.  Fig.  2 
shows Kaplan-Meier estimates of time to treatment 
failure.  Median time to treatment failure was 2.7 
months.
Discussion
　 Toremifene citrate has been shown to be an aﬃnity 
substrate for the p-glycoprotein [12] and has chemo-
sensitizing activity in MDR-positive cells at concen-
190 Acta Med.  Okayama　Vol.  63,  No.  4Okita et al.
Table 2　 Characteristics of initial tumor
Initial tumor site Right 6
Left 8
Bilateral 1





Estrogen receptor Positive 11
Negative 4
HER2（IHC） 0, 1＋ 13
　2＋ 2
Table 3A　 Non-hematological toxicities
Before entry Paclitaxel Paclitaxel＋toremifene
G1 G2 G1 G2 G1 G2
Nausea/vomiting  1 0  5  0  6 1
Stomatitis  0 0  2  0  3 1
Alopecia  6 4  8  6  2 13
Sensory neuropathy (Numbness) 10 0 11  0 11 1
Myalgia/Arthralgia  2 0  3  0  5 1
Flushing  0 0 14  0 13 0
Fatigue  3 0  8  0  7 2
Taste disturbance  1 0  3  0  3 0
Edema  0 3  3  3  2 3
Lethargy  0 0  3  0  3 0
Vaginal discharge  0 0  0  0  0 3
Cough  4 0  4  0  4 0
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trations that are achieved in humans with minimal 
toxicity,  although the mechanism underlying the 
modulation of multidrug resistance is unknown [19-
22].  The development of MDR is one of the major 
mechanisms by which cancer becomes refractory to 
chemotherapeutic agents [21] and mechanisms of the 
MDR phenotype may involve p-glycoprotein expres-
sion,  topoisomerases,  and multidrug resistance-asso-
ciated protein [7].  P-glycoprotein is overexpressed in 
approximately 40ｵ of breast cancers and is associ-
ated with resistance to drugs of plant or bacterial 
origin [7].  In addition,  drug resistance may arise 
with high baseline levels or increased expression lev-
els of p-glycoprotein as a consequence of treatment 
[23].  A meta-analysis by Trock BJ et al.  showed that 
patients are twice as likely to be MDR-positive follow-
ing treatment,  suggesting that treatment increased the 
expression of p-glycoprotein [7,  23].
　 A major problem with many reversing agents is 
that they can signiﬁcantly alter the pharmacokinetics 
of the cytotoxic agents with which they are coadminis-
tered and increase the toxicity of the regimen [23,  
24].  Valspodar and elacridar were developed as 
p-glycoprotein inhibitors in clinical trials [25].  These 
inhibitors modiﬁed the pharmacokinetic parameters of 
chemotherapeutic agents,  which suggests that p-glyco-
protein inhibition mediates the metabolism of anti-
cancer drugs.  However,  Dofequidar fumarate,  a new 
p-glycoprotein inhibitor,  was shown to improve the 
progression-free survival of metastatic breast cancer 
patients,  but it did not modify the area under the 
curve (AUC) of doxorubicin in a study by Saeki et al.  
[26].  Toremifene is extensively metabolized by 
CYP3AP and to a minor extent,  by other hepatic 
191Paclitaxel and ToremifeneAugust 2009
Table 3B　 Hematological toxicities
Before entry Paclitaxel Paclitaxel＋toremifene
G1 2 3 4 G1 2 3 4 G1 2 3 4
Leukopenia 0 0 0 0 4 5 2 0 3 2 1 0
Hemoglobin decreased 3 1 0 0 7 2 0 0 4 4 0 0
Febrile neutropenia 0 0 0 0 0 0 0 0 0 0 1 0
Glutamic oxaloacetic transaminase increased 3 1 0 0 6 0 0 0 2 1 0 0
Glutamic pyruvic transaminase increased 3 0 0 0 7 0 0 0 3 1 0 0
Bilirubin increased 1 0 0 0 0 0 0 0 0 0 0 0
Gamma-glutamyl transpeptidase increased 3 0 1 0 4 2 0 0 0 5 0 0
Alkaline phosphatase increased 6 1 0 0 9 0 0 0 4 1 0 0
Hypoalbuminemia 2 0 0 0 4 0 0 0 6 0 0 0
Hypercholesterolemia 7 0 0 0 7 0 0 0 4 0 0 0
Hypertriglyceridemia 5 0 0 0 6 0 0 0 7 0 0 0
Proteinuria 2 0 0 0 5 0 0 0 3 0 0 0
Hematuria 3 0 0 0 4 0 0 0 2 0 0 0
Table 4　 Summary of eﬃcacy results: response rate
Tumor response No. of patients (%)
CR 0 ( 0%)
PR 1 ( 6.7%)
NC ≧6 months 4 (26.7%)
＜6 months 6 ( 40%)
DCR 5 (33.3%)
PD 4 (26.7%)
CR,  complete response; PR,  partial response; NC,  no change;  
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Fig. 2　 Kaplan-Meier curve for time to treatment failure.
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isozymes [14].  Paclitaxel was also metabolized by 
cytochrome P450 enzymes of the CYP3A and CYP2C 
subfamilies in hepatic metabolism [13].  The coadmin-
istration of these agents with a common metabolic 
pathway may appear to inﬂuence drug concentration 
and increase adverse eﬀects.  Some p-glycoprotein 
inhibitors have been shown to modulate the pharma-
cokinetic parameters of chemotherapeutic agents in 
pre-clinical and clinical studies,  and these inhibitors 
often enhanced toxicity as evidenced by an increase in 
the AUC of anti-cancer agents.  However,  concerning 
drug resistance,  the concurrent use of chemothera-
peutic and endocrine agents may be reasonable.
　 Weekly paclitaxel therapy was well-tolerated,  with 
favorable safety and eﬃcacy [27].  In previously 
published reports on weekly paclitaxel treatment (80-
100mg/m2 per week) [28,  29],  the toxicity was mild 
and consisted mainly of neutropenia and neuropathy.  
Severe adverse events included 14-18ｵ grade 3-4 
neutropenia,  and 4-24ｵ severe neuropathy.  Myalgia 
and arthralgia were common but rarely severe.  
Toremifene has been also considered to be a promising 
agent with no serious side eﬀects for use in breast 
cancer treatment [30,  31].  In phase III trials of 
standard or high-dose regimen comparisons,  adverse 
events in patients who received 60-mg/day standard 
doses occurred in less than 20ｵ of the patients [32],  
and frequent adverse events included hot ﬂashes,  
sweating,  nausea and/or vomiting,  vaginal discharge,  
dizziness,  edema,  vaginal bleeding,  liver function 
abnormalities,  ocular changes and thromboembolic or 
cardiac events [32-34].  With high doses of tore-
mifene (200 or 240mg) in phase III studies,  there was 
a trend toward more nausea,  reversible corneal ker-
atopathy,  clinically insigniﬁcant serum glutamic 
oxaloacetic transaminase elevations,  and hypercalce-
mia compared with tamoxifen [33,  34].  Toremifene 
appeared equally tolerated at high (up to 240mg) and 
low (60mg) dosage with the exception of a signiﬁ-
cantly higher incidence of nausea at high dosage in one 
study [19,  35].  In Japan,  high-dose toremifene at 
120mg/day is approved for the treatment of patients 
refractory to tamoxifen or other agents.  In a phase II 
study by Asaishi et al,  adverse events occurred in 
5.1ｵ of patients and included nausea,  vertigo,  and 
abnormal liver function [36].  It is noted that in our 
study compared with other studies,  most patients were 
treated heavily with prior chemotherapy.  They had 
already complained of various symptoms or had abnor-
mal laboratory data reﬂecting side eﬀects.  Although 
this study was conducted over a relatively short 
period,  all patients tolerated the treatment well.  
Only 1 patient (6.7ｵ) had grade 3 neutropenia and for 
this patient,  the administration of paclitaxel was often 
postponed until neutropenia improved and the treat-
ment was continued with prophylaxis G-CSF.  In the 
follow-up study,  1 patient complained of grade 3 sen-
sory neuropathy and declined to continue the therapy.  
No other patients experienced severe adverse events 
and continued to receive the therapy until tumor pro-
gression.  Actually,  some studies showed an increase 
in hematological toxicities by the addition of a p-glyco-
protein modulator [25].  In our study,  pharamacoki-
netics interactions between toremifene and paclitaxel 
were under the investigation,  but the dose reduction 
may be needed,  depending on the analysis.
　 The beneﬁts of chemoendocrine therapy compared 
to hormonal therapy or chemotherapy remains unclear.  
As for the adjuvant chemoendocrine therapy,  a study 
of the SWOG 8814 trial showed that the sequential 
use of tamoxifen with cyclophosphamide,  doxorubicin,  
and 5-ﬂuorouracil in postmenopausal women with 
hormone receptor-positive,  node-positive breast can-
cer resulted in better disease-free survival compared 
to their concurrent use [37].  In advanced or meta-
static breast cancer,  combining hormonal therapy with 
chemotherapy was considered to have a potential 
beneﬁt through additive or synergistic cytotoxicity in 
hormone receptor-positive breast cancer [38].  But 
previous studies show no survival advantage for the 
addition of hormonal therapy to chemotherapy com-
pared to sequential therapy [38].  In our study,  
because most patients receiving previous various 
therapies acquired multidrug resistance,  chemosensi-
tizing activity rather than additive or synergistic 
cytotoxicity would be expected.
　 Paclitaxel is an eﬀective agent in the treatment of 
metastatic breast cancer and administration schedules 
of weekly paclitaxel by 1-hour infusion at doses rang-
ing from 80 to 100mg/m3 has achieved overall 
response rates of 50-68ｵ [39].  In pretreated 
patients with metastatic breast cancer,  response rates 
were in the range of 22-53ｵ with a median time to 
progression of 5-6 months [29].  On the other hand,  
in a large phase III study of toremifene therapy for 
advanced breast cancer,  response rates in the high-
192 Acta Med.  Okayama　Vol.  63,  No.  4Okita et al.
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dose toremifene arms were 22.6ｵ in the North 
American Trial [35] and 28.7ｵ in the Eastern 
European Trial [40],  with a median time to progres-
sion from 5.5 to 6.1 months.  Furthermore,  high-dose 
toremifene therapy (120 to 240mg/day) in a phase II 
study in patients with advanced breast cancer refrac-
tory to tamoxifen therapy achieved a 0 to 14ｵ objec-
tive response rate,  and a 19 to 44ｵ disease stabiliza-
tion during toremifene treatment with a median 
duration of disease stabilization of more than 2 
months [19].  In a Japanese phase II study,  Asaishi et 
al.  reported that 120mg of toremifene daily achieved 
an objective response rate of 14ｵ and disease stabili-
zation of 19ｵ in patients with tamoxifen-refractory 
breast cancer [19,  36].  In our study,  most of the 
patients had already been exposed and become refrac-
tory to various chemotherapeutic or endocrine agents.  
Notably,  our study included 11 (73ｵ) patients 
exposed to taxanes.  In this disadvantageous state,  
objective response and disease stabilization were 
observed in 1 (6.7ｵ) and 4 (26.7ｵ) patients,  respec-
tively.  Overcoming drug resistance is highly suspected 
beyond our expectations.
　 In conclusion,  the results of this study demon-
strate the tolerability and eﬀectiveness of paclitaxel 
combined with toremifene in patients with metastatic 
breast cancer.  Only 1 patient partially responded in 
terms of the suspected release of drug resistance.  
This result is promising in patients previously exposed 
to multi-drug therapy.  In addition in deteriorated 
patients,  this therapy is safe and tolerant as salvage 
chemotherapy.  However,  this study was small and did 
not require p-glycoprotein expression for inclusion.  
We believe that further clinical trials targeting 
patients with a functional p-glycoprotein are war-
ranted.
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